賽諾菲香港致力解決主要健康問題,為大眾提供健康防護方案。
處方藥物, 監督售賣藥物*及醫療儀器# (僅供專業醫護人員參考)
- Adenoscan (adenosine)
- Aldurazyme (laronidase)
- Alprolix (Eftrenonacog alfa)
- Amaryl (glimepiride)
- Apidra* (insulin glulisine)
- Aprovel 卡壓舒 (irbesartan) and Co-Aprovel 樂壓舒 (irbesartan and hydrochlorothiazide)
- Arava (leflunomide)
- Aubagio (teriflunomide)
- Caprelsa (vandetanib)
- Cerezyme (imiglucerase)
- Claforan (cefotaxime sodium)
- Clexane (enoxaparin)
- Cordarone (amiodarone)
- Danocrine (danazol)
- Dupixent 特倍善® (Dupilumab 度匹蘆人單抗)
- Elaprase (idursulfase)
- Eloctate (Efmoroctocog alfa)
- Eloxatin 樂沙定 (oxaliplatin)
- Epilim 穩得寧 (sodium valproate) and Epilim Chrono (sodium valproate and valproic acid)
- Evoltra (clofarabine)
- Fabrazyme (agalsidase beta)
- Fasturtec (rasburicase)
- Flagyl (metronidazole)
- Fludara (fludarabine phosphate)
- Frisium (clobazam)
- Imovane (zopiclone)
- Jevtana (cabazitaxel)
- Kevzara (sarilumab)
- Lantus 理糖適* (insulin glargine 100 unit/mL)
- Lasix (furosemide)
- Lemtrada (alemtuzumab)
- Mozobil (plerixafor)
- Multaq 心韻定 (dronedarone)
- Myozyme (alglucosidase-alfa)
- Panadine (paracetamol + codeine phosphate)
- Pentacarinat (pentamidine diisetionate)
- Plaquenil (hydroxychloroquine sulfate)
- Plavix 柏域斯 (clopidogrel) and CoPlavix (clopidogrel and acetylsalicylic acid)
- Praluent 柏力仁 (alirocumab)
- Priftin (rifapentine)
- Primacor (milrinone lactate)
- Primperan (metoclopramide)
- Renvela (sevelamer carbonate)
- Resonium* (calcium/sodium polystyrene sulphonate)
- Rifadin (rifampicin)
- Rilutek (riluzole)
- Sabril (vigabatrin)
- Sarclisa (Isatuximab)
- Solian 樂靈逸 (amisulpride)
- Soliqua (Insulin glargine + Lixisenatide)
- Stilnox 瑞樂時 (zolpidem)
- Stilnox CR 長效瑞樂時 (zolpidem)
- Surmontil (trimipramine maleate)
- Synvisc# and Synvisc-One# (Hylan G-F 20)
- Taxotere 特素療 (docetaxel)
- Thymoglobuline (Rabbit anti-human thymocyte immunolgloblin)
- Thyrogen (thyrotropin alfa)
- Toujeo* (insulin glargine 300 unit/mL)
- Trental (pentoxifylline)
- Tritace (ramipril)
- Xatral (alfuzosin)
- Zaltrap (aflibercept)
MAT-HK-2200059-1.0-03/2022